Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
This study is ongoing, but not recruiting participants.
Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by RAC.
Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PHASE 3 MULTI-CENTER RANDOMIZED STUDY TO COMPARE EFFICACY AND SAFETY OF ROMIDEPSIN CHOP (Ro-CHOP) VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA
Condition: Peripheral T-Cell Lymphoma
Drug: Romidepsin + CHOP
Phase: Phase 3
External Link: https://clinicaltrials.gov/show/NCT01796002